This month we hear from Mark Grumbridge, Head of Clinical Investigations, MHRA.
The Medicines and Healthcare products Regulatory Agency (MHRA) plays a critical role in protecting public health by ensuring that medicines and medical devices in the UK meet robust standards of safety, quality and performance. As part of this mission, the MHRA has recently strengthened its presence in Northern Ireland – an important step that reflects both the region’s unique regulatory position and its growing potential as a centre for clinical research and innovation.
Northern Ireland operates within a distinctive regulatory environment, where aspects of European Union legislation continue to apply alongside UK frameworks. While this dual system can present complexity for researchers and sponsors, it also offers a significant opportunity – particularly for those seeking to generate evidence that supports access to both UK and EU markets. Strengthening the MHRA’s presence locally allows us to better support stakeholders navigating this landscape and ensure that regulatory oversight remains both proportionate and accessible.
From my perspective as Head of Clinical Investigations, this is an important development. Regulatory systems work best when they are not only rigorous, but also visible and engaged. By being closer to the research community in Northern Ireland, we are better able to understand emerging challenges, respond more effectively, and support high-quality clinical investigations from the outset.
Supporting a Clear and Navigable Regulatory Environment
A key part of the MHRA’s role is to provide clarity and assurance within a complex regulatory framework. In Northern Ireland, this includes helping organisations understand how the UK Medical Device Regulations (MDR) and EU MDR or In Vitro Diagnostic Medical Devices Regulation (IVDR) requirements interact, particularly in the context of clinical investigations and performance studies.
Our strengthened presence enables more direct engagement with sponsors, researchers and healthcare organisations. This helps ensure that regulatory considerations are embedded early in study design, reducing the risk of delays and improving the overall quality of applications. It also supports a more consistent interpretation of requirements, which is particularly important in a dual-regulatory setting.
In my experience, early dialogue between regulators and innovators is one of the most effective ways to support both compliance and innovation. It allows potential issues to be identified early and helps ensure that evidence generation strategies are aligned with regulatory expectations from the start.
Enabling Innovation in Medicines and Medical Devices
Northern Ireland has a strong and evolving life sciences ecosystem, with significant expertise across academia, healthcare and industry. The MHRA’s role is to ensure that innovation can progress within a framework that maintains patient safety and public confidence.
This includes providing regulatory advice on clinical investigations, supporting novel approaches such as digital technologies and in-silico methods, and helping developers navigate the pathway from early research through to market access. By engaging early and constructively, we can help innovators design studies that generate meaningful, high-quality evidence.
From a clinical investigations perspective, I can see clear benefits in being able to engage more directly with developers working on emerging technologies. The pace of innovation – particularly in areas such as software-based devices and advanced diagnostics – means that regulatory approaches must be responsive and informed. Greater local presence allows us to have those discussions in a more timely and effective way.
The Value of Face-to-Face Engagement
One of the most tangible benefits of an increased MHRA presence in Northern Ireland is the opportunity for face-to-face engagement. While digital channels are essential, in-person discussions remain invaluable when dealing with complex or nuanced regulatory issues.
Face-to-face engagement allows for more detailed and iterative conversations, helping to resolve questions that might otherwise take longer to address. It also strengthens relationships between regulators and the research community, fostering a collaborative approach to problem-solving.
From my own experience, some of the most productive regulatory discussions come from direct interaction – where we can explore challenges in detail and jointly identify practical, proportionate solutions. This is particularly important when considering novel technologies or borderline cases, where regulatory interpretation is not always straightforward.
Expanding Opportunities for Clinical Research
A more visible and accessible regulatory presence supports broader ambitions to increase clinical research activity in Northern Ireland. By providing clear and timely advice, the MHRA helps to create a more attractive environment for sponsors considering where to locate clinical investigations and performance studies.
This can support greater investment, stronger collaboration between industry and healthcare providers, and increased participation in research. For researchers, it means improved access to regulatory expertise; for sponsors, it provides greater confidence in navigating the regulatory process.
Delivering Benefits for Patients and the Public
Ultimately, the purpose of strengthening regulatory presence and supporting research is to improve outcomes for patients and the public.
In my view, this development has several important benefits:
- Improved access to innovative treatments: Increased research activity provides patients with opportunities to participate in studies involving cutting-edge therapies and technologies.
- Enhanced patient safety: Close regulatory oversight ensures that investigations are conducted to the highest standards.
- Greater equity of access: Expanding research in Northern Ireland helps ensure that patients are not disadvantaged by geography when it comes to accessing clinical trials.
- Faster translation into practice: Effective regulatory engagement helps accelerate the pathway from innovation to clinical use.
Looking Ahead
The MHRA’s strengthened presence in Northern Ireland is about more than proximity – it is about developing a more collaborative, responsive and accessible regulatory system.
As Head of Clinical Investigations, I see this as a significant opportunity to deepen engagement with the research community, support high-quality evidence generation, and ultimately improve patient outcomes. By working together with researchers, healthcare providers and industry, we can help ensure that Northern Ireland continues to grow as a key location for safe, innovative and impactful clinical research.
